IgA Nephropathy Market
As per DelveInsight, IgA Nephropathy prevalence was 377,829 cases in the 7MM (the US, EU5 and Japan) in 2020, with the US accounting for the maximum number of IgAN prevalent cases. Moreover, it was observed that IgAN occurs twice more in men as compared to women. Although, most of the cases predominantly falls in the age group of 19â45 years. IgA Nephropathy market is expected to transform in the coming years with the launch of novel therapeutic assets.
Leading pharma companies such as Calliditas Therapeutics AB, Chinook Therapeutics, Inc., Novartis, Omeros Corporation, among others are enthusiastically working at the therapeutics front to transform the market outlook with a standard and curative approach.
For more details, visit:Â IgA Nephropathy Market














